ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Abdominal infection | 11.01.07.014; 07.19.02.007 | 0.000139% | | |
Staphylococcal infection | 11.02.05.002 | 0.000533% | | Not Available |
Angiopathy | 24.03.02.007 | - | - | Not Available |
Metastases to central nervous system | 17.02.10.013; 16.22.02.004 | 0.001112% | | Not Available |
Skin toxicity | 12.03.01.020; 23.03.03.032 | 0.001066% | | Not Available |
Blood alkaline phosphatase increased | 13.04.02.004 | 0.000533% | | |
Urine output decreased | 13.13.03.001 | 0.000533% | | |
Hepatic enzyme increased | 13.03.01.019 | 0.001066% | | Not Available |
Brain neoplasm | 17.20.01.003; 16.30.01.003 | 0.000208% | | Not Available |
Cardiac disorder | 02.01.01.003 | - | - | Not Available |
Connective tissue disorder | 15.06.01.006 | - | - | Not Available |
Ocular toxicity | 06.11.01.006; 12.03.01.031 | - | - | Not Available |
Infestation | 23.09.05.001; 11.09.01.001 | - | - | Not Available |
Inflammation | 08.01.05.007 | 0.000799% | | Not Available |
Malnutrition | 14.03.02.004 | - | - | Not Available |
Mediastinal disorder | 22.09.03.001 | - | - | Not Available |
Mental disorder | 19.07.01.002 | - | - | Not Available |
Decreased appetite | 14.03.01.005; 08.01.09.028 | 0.004529% | | |
Polyp | 16.02.02.005; 08.01.06.010 | - | - | Not Available |
Disease progression | 08.01.03.038 | 0.001807% | | |
Drug intolerance | 08.06.01.013 | - | - | Not Available |
Investigation | 13.18.01.004 | 0.000208% | | Not Available |
Metastasis | 16.22.01.001 | 0.000139% | | Not Available |
Respiratory tract infection | 22.07.07.001; 11.01.08.017 | 0.001598% | | Not Available |
Hypophagia | 19.09.01.004; 14.03.01.006; 07.01.06.010 | 0.000533% | | Not Available |
Thyroid cancer | 16.24.03.001; 05.02.05.001 | 0.000139% | | Not Available |
Oropharyngeal pain | 22.02.05.022; 07.05.05.004 | - | - | |
Acute kidney injury | 20.01.03.016 | 0.002131% | | |
Langerhans' cell histiocytosis | 22.01.01.016; 16.21.04.003; 15.09.03.008; 01.13.04.003 | 0.001332% | | Not Available |
Drug reaction with eosinophilia and systemic symptoms | 23.03.05.005; 10.01.01.021 | 0.001066% | | Not Available |